Oklahoma Personal Injury News
Product Liability News from Law360.com
‑Study Says Meridia May Up Risk Of Heart Attack, Stroke
A study published Thursday in The New England Journal of Medicine warned that Abbott Laboratories’ weight-loss drug Meridia may increase the risk of nonfatal heart attack and stroke in some users, raising new concerns about the controversial pill just weeks before a U.S. advisory panel is set to consider its fate. [Link]
‑GSK Paxil Suit Transferred From Minn. To NJ
A federal judge has transferred a proposed class action accusing GlaxoSmithKline PLC of misrepresenting the safety and efficacy of its antidepressant treatment Paxil from Minnesota to New Jersey, saying the case “bears little to no connection with Minnesota.” [Link]
‑Allergan Settles Botox Off-Label Claims For $600M
Allergan Inc. reached a $600 million settlement with the U.S. Department of Justice on Wednesday to resolve criminal and civil claims stemming from the company's marketing of off-label uses for its blockbuster wrinkle-treating drug Botox. [Link]
‑FDA Tells Baxter To Tone Down Aralast Claims
The U.S. Food and Drug Administration has issued a warning letter chastising Baxter International Inc. for overstating the effectiveness of Aralast, a lung therapy for patients at risk for a form of hereditary emphysema. [Link]
‑Most Admired Attys: Pepper Hamilton's Nina Gussack
Pepper Hamilton LLP's Nina Gussack has proved tough enough to tackle state attorneys general on behalf of pharmaceutical giants while making sure that even new associates in the firm's health effects group play an active role in the litigation team, earning her a spot as one of Law360's 10 Most Admired Product Liability Attorneys. [Link]
‑FDA Warns Sun Over Oxycodone Quality Control Issues
The U.S. Food and Drug Administration has faulted a unit of Sun Pharma Global Inc. for lapses in quality control the regulator blames for “imploding” bottles of gemfibrozil, “sweating” nimodipine capsules and misplaced oxycodone pills. [Link]